ATE291919T1 - Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen - Google Patents

Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen

Info

Publication number
ATE291919T1
ATE291919T1 AT00979157T AT00979157T ATE291919T1 AT E291919 T1 ATE291919 T1 AT E291919T1 AT 00979157 T AT00979157 T AT 00979157T AT 00979157 T AT00979157 T AT 00979157T AT E291919 T1 ATE291919 T1 AT E291919T1
Authority
AT
Austria
Prior art keywords
adatanserin
treatment
neurodegenerative diseases
acute neurodegenerative
treating
Prior art date
Application number
AT00979157T
Other languages
English (en)
Inventor
Magid Abdel-Megid Abou-Gharbia
James Edward Barrett
Wayne Everett Childers Jr
John Allen Moyer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE291919T1 publication Critical patent/ATE291919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)
AT00979157T 1999-11-12 2000-11-10 Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen ATE291919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43921999A 1999-11-12 1999-11-12
PCT/US2000/030973 WO2001034136A2 (en) 1999-11-12 2000-11-10 Use of adatanserin for the treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
ATE291919T1 true ATE291919T1 (de) 2005-04-15

Family

ID=23743796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979157T ATE291919T1 (de) 1999-11-12 2000-11-10 Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen

Country Status (22)

Country Link
EP (2) EP1547597A3 (de)
JP (1) JP2003513915A (de)
KR (1) KR100757226B1 (de)
CN (1) CN100469368C (de)
AT (1) ATE291919T1 (de)
AU (1) AU773733B2 (de)
BR (1) BR0015523A (de)
CA (1) CA2390797A1 (de)
CZ (1) CZ298535B6 (de)
DE (1) DE60019166T2 (de)
EA (1) EA006099B1 (de)
ES (1) ES2235998T3 (de)
HK (1) HK1046505B (de)
HU (1) HUP0301847A3 (de)
IL (1) IL149264A0 (de)
MX (1) MXPA02004654A (de)
NO (1) NO322371B1 (de)
NZ (1) NZ518814A (de)
PL (1) PL355014A1 (de)
PT (1) PT1242089E (de)
WO (1) WO2001034136A2 (de)
ZA (1) ZA200204682B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2390797A1 (en) * 1999-11-12 2001-05-17 Wyeth Methods for the treatment and prevention of neurodegenerative conditions
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
CA2390797A1 (en) * 1999-11-12 2001-05-17 Wyeth Methods for the treatment and prevention of neurodegenerative conditions

Also Published As

Publication number Publication date
IL149264A0 (en) 2002-11-10
CA2390797A1 (en) 2001-05-17
HK1046505B (zh) 2005-06-03
DE60019166T2 (de) 2006-05-11
NZ518814A (en) 2005-08-26
CN100469368C (zh) 2009-03-18
ZA200204682B (en) 2003-09-11
WO2001034136A2 (en) 2001-05-17
WO2001034136A3 (en) 2002-03-21
EA006099B1 (ru) 2005-08-25
MXPA02004654A (es) 2004-09-10
AU1656701A (en) 2001-06-06
DE60019166D1 (de) 2005-05-04
PL355014A1 (en) 2004-03-22
NO20022187L (no) 2002-05-07
BR0015523A (pt) 2002-10-22
CZ20021629A3 (cs) 2003-06-18
EP1547597A2 (de) 2005-06-29
ES2235998T3 (es) 2005-07-16
EP1242089A2 (de) 2002-09-25
PT1242089E (pt) 2005-08-31
KR100757226B1 (ko) 2007-09-11
JP2003513915A (ja) 2003-04-15
EP1547597A3 (de) 2006-09-27
KR20020073132A (ko) 2002-09-19
EP1242089B1 (de) 2005-03-30
CN1390128A (zh) 2003-01-08
CZ298535B6 (cs) 2007-10-31
HUP0301847A2 (hu) 2003-09-29
HK1046505A1 (en) 2003-01-17
NO20022187D0 (no) 2002-05-07
AU773733B2 (en) 2004-06-03
HUP0301847A3 (en) 2004-01-28
NO322371B1 (no) 2006-09-25
EA200200559A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE366581T1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE291919T1 (de) Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69430807T2 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
RU94013606A (ru) Гемостимулятор
RU95117774A (ru) Способ лечения хронических воспалительных заболеваний верхних дыхательных путей
RU97110384A (ru) Способ лечения вибрационной болезни

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242089

Country of ref document: EP

REN Ceased due to non-payment of the annual fee